Share
831 Posts.
lightbulb Created with Sketch. 222
clock Created with Sketch. 05/04/25
12:16
Share
Originally posted by Eagle0:
↑
I'm probably suffering confirmation bias given I was a previous shareholder of Clinvuel, but Clinuvel's share price has been totally controlled by shorts of the past several years and when an event hits like what happened with the tariffs recently its my view that the shorts will take advantage of the general downturn in the markets and push the sp further down to profit on their short bets.
Expand
CUV has an annual revenue of over 70 million,with a phase III clinical trial of vitiligo, 200 million in cash, and a market value of 520 million. Neu has an annual revenue of 60 million, is about to enter phase III, and has 300 million in cash. I have always been worried that the shorts will control Neu like they control CUV. Then Neu's market value will reach 520 million, $4-5 per share, which is not impossible?
(20min delay)